Prostate-specific antigen as a risk factor for skeletal metastasis in native ethnic African Men with prostate cancer : a case control study
| Autor: | Khalid Makhdomi, William Stones, Ayman M Qureshi |
|---|---|
| Přispěvatelé: | University of St Andrews. School of Medicine, University of St Andrews. Global Health Implementation Group |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Oncology
lcsh:Medical physics. Medical radiology. Nuclear medicine medicine.medical_specialty skeletal metastases lcsh:R895-920 Population NDAS Native ethnic African native ethnic African 030218 nuclear medicine & medical imaging RC0254 03 medical and health sciences Prostate cancer 0302 clinical medicine SDG 3 - Good Health and Well-being Internal medicine Medicine prostate-specific antigen Risk factor education Skeletal metastases education.field_of_study business.industry RC0254 Neoplasms. Tumors. Oncology (including Cancer) Mortality rate Case-control study Cancer Odds ratio Bone scan medicine.disease prostate cancer Prostate-specific antigen 030220 oncology & carcinogenesis Original Article business |
| Zdroj: | World Journal of Nuclear Medicine, Vol 16, Iss 1, Pp 26-32 (2017) World Journal of Nuclear Medicine |
| ISSN: | 1607-3312 1450-1147 |
| Popis: | Prostate cancer is the commonest non cutaneous cancer in males. Men of African origin are at significantly higher risk as reflected in higher incidence and mortality rates in this racial group. Metastases incidence increases in parallel with serum levels of Prostate Specific Antigen (PSA), contributing significantly to morbidity and mortality. Staging of disease involves bone scans, which are sensitive in detecting skeletal metastases. Suggestions they may be omitted in some situations in patients with low prostate specific antigen levels, have drawn attention to the matter. In this case control study, using Radiology and Pathology records, a registry of prostate cancer patients recorded as being of Black African ethnicity was assembled. Images were presented to image reviewers blinded to the prostate specific antigen level, to determine presence of skeletal metastases. The risk factor for the outcome of interest (skeletal metastases) was prostate specific antigen level above 20ng/ml. Reliability of image reporting was also assessed. Of 122 patients, 50 (41%) had skeletal metastases, while these were absent in 72 (59%). The prevalence of metastases among the high prostate specific antigen group was 55.9% (95% CI 44.1% to 67.7%) and 22.2% (95% CI 11.1% to 33.3%) among the normal/low prostate specific antigen group. The Odds Ratio (OR) for skeletal metastases in the exposed (high prostate specific antigen) group was 4.4 (95% CI, 2.01 to 9.78.) Intra-observer agreement on image interpretation was 88.5% with a Kappa statistic of 0.76. Relatively higher prevalence of skeletal metastasis is seen in regional Black African males with prostate cancer, at both low and high prostate specific antigen levels. Bone scanning in this population should therefore be considered even at prostate specific antigen levels below 20ng/ml. Publisher PDF |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|